Ovarian cancer has long presented immunologists with a stubborn paradox. Under the microscope, high-grade serous carcinoma, the most common and aggressive form of the disease, is often crowded with T cells, the very immune soldiers that should in theory mount a devastating attack on the tumor. Yet patient outcomes remain stubbornly poor. A new review published in Discover Immunity argues that the answer lies in a sophisticated, multi-layered immunosuppressive tumor microenvironment that does not merely tolerate immune infiltration but actively weaponizes it, with regulatory T cells, or Tregs, serving as the chief architects of immune evasion.
Tregs are defined by the expression of the CD4 surface marker and the master transcription factor FoxP3. In healthy physiology, they are indispensable: they maintain peripheral immune tolerance and prevent the body from turning on itself in severe autoimmune disease. In cancer, however, that potent suppressive capacity is aggressively co-opted by the malignant microenvironment to promote tumor progression and shield the tumor from immune destruction. The review, authored by Chinmoy K Bose, traces roughly three decades of research on these cells in ovarian cancer, from the lineage’s discovery in the mid-1990s to the highly targeted translational strategies now under clinical evaluation.
The scientific foundation was laid in 1995, when Sakaguchi and colleagues identified a stable subset of thymus-derived CD4+ T cells expressing high levels of the interleukin-2 receptor alpha-chain, CD25, and demonstrated that this population could protect thymectomized mice from autoimmunity. The defining molecular feature, stable FoxP3 expression maintained through epigenetic modifications at the Treg-specific demethylated region, was identified later and proved transformative for human cancer research. Before FoxP3, studies had to rely on the CD4+CD25+ phenotype alone, a confounded approach because activated effector T cells transiently express CD25, often inflating estimates of the true suppressive population.
The first definitive link between Tregs and human ovarian cancer came in 2001, when researchers documented significantly increased percentages of CD4+CD25+ cells in patients with late-stage disease. A landmark 2004 publication then established that the accumulation of Tregs in ovarian tumors and ascitic fluid is an active process, and one linked to reduced patient survival. The primary mechanism is chemokine-mediated trafficking: tumor cells and tumor-associated macrophages secrete CCL22, and Tregs, which abundantly express the corresponding receptor CCR4, migrate rapidly along this gradient into the peritoneal cavity and tumor tissue. This recruitment pathway fosters a state of immune privilege that protects the tumor from potentially effective anti-tumor immune destruction.
By the mid-2000s, the field had converged on a powerful prognostic metric. A pivotal 2005 study formally established the CD8+/Treg ratio as an essential immunological index in epithelial ovarian cancer, demonstrating that the unfavorable prognostic effect previously attributed to total CD4+ T cells was specifically attributable to the suppressive CD25+FOXP3+ population within that lineage. The quantitative findings were striking: patients with a high intraepithelial CD8+/Treg ratio had a median survival of 58 months, compared with only 23 months for those with a low ratio, a hazard ratio of 0.31 with a P value of 0.0002, corresponding to an almost 70 percent reduction in the risk of death. Cancer progression, the review argues, is essentially dictated by this immunological tug-of-war rather than by the absolute count of any single cell type.
Mechanistic dissection since the late 2000s has revealed a TME of remarkable redundancy. Beyond the CCL22/CCR4 axis, the CXCR4/CXCL12 pathway contributes to trafficking, its functional expression often induced by prostaglandin E2. Cytokines play a dual role, recruiting thymic-derived Tregs and inducing naive CD4+ T cells to differentiate into peripheral Tregs. TGF-beta, secreted at high levels by ovarian cancer cells and tumor-associated macrophages, drives the generation of inducible Tregs and maintains their suppressive phenotype, and neutralizing it has been shown to inhibit tumor progression while enhancing the favorable CD8+/Treg ratio. IL-6 promotes expression of TNFR2 on Tregs, whose subsequent signaling drives rapid Treg proliferation and upregulation of inhibitory molecules such as PD-L1, CTLA-4 and GARP, while simultaneously suppressing IFN-gamma production by effector T cells.
Metabolic manipulation adds a further layer of suppression. Malignant ascites, common in advanced disease, perturbs glucose uptake and selectively impairs the metabolism and function of effector T cells. Tregs themselves display metabolic flexibility, relying preferentially on lipid oxidation and oxidative phosphorylation, and can even absorb lactate secreted by tumor cells to fuel their own tricarboxylic acid cycle. Tregs also constitutively express the ectonucleotidases CD39 and CD73, which convert extracellular ATP into immunosuppressive adenosine, shutting down T cell receptor signaling through A2A receptors. Meanwhile, the IDO pathway degrades tryptophan into kynurenine, starving effector T cells and simultaneously driving naive T cells toward a regulatory fate through the aryl hydrocarbon receptor.
Phenotypic complexity has also reshaped prognostic thinking. In 2015, researchers identified a subset of tumor-infiltrating lymphocytes with the phenotype CD4+CD25+FoxP3−: highly activated, functionally exhausted, expressing the highest levels of PD-1 among all CD4+ TILs, and failing to produce IFN-gamma, TNF-alpha, IL-2 or IL-17A upon restimulation. Critically, the presence of these exhausted cells was strongly associated with improved survival in high-grade serous carcinoma, showing a favorable hazard ratio of 0.56 (P = 0.02) in tumors containing cytotoxic CD8+ TILs. These cells appear to be former anti-tumor effectors driven to anergy by the chronic suppressive environment, and their existence provides a rationale for immune checkpoint inhibitors intended to relieve exhaustion and re-awaken them.
Translational efforts have shifted accordingly, away from non-selective strategies toward precision immunotherapy. Early metronomic chemotherapy with low-dose cyclophosphamide produced only transient decreases in Treg frequencies and limited clinical benefit, a shortfall underscored by a phase 2 randomized trial in which the entirely oral combination of metronomic cyclophosphamide and the angiokinase inhibitor nintedanib showed negligible improvement, with median progression-free survival of 2.9 months versus 2.6 months compared with cyclophosphamide alone. Current trials instead focus on selective depletion via anti-CCR4 antibodies such as mogamulizumab, designed to eliminate CCR4+ effector Tregs at the disease site while preserving peripheral tolerance, and on E7777, a targeted Treg-depleting agent being evaluated in a phase I/II study combined with pembrolizumab in recurrent or metastatic solid tumors including epithelial ovarian cancer.
Next-generation modalities aim to destabilize Tregs rather than simply delete them. Agonistic antibodies against GITR and OX40 are designed to drive intratumoral Treg lineage instability and apoptosis while simultaneously co-stimulating cytotoxic CD8+ T cells, with active trials including INCAGN01876 in advanced solid tumors. Bifunctional TGF-beta/PD-L1 antibodies such as bintrafusp alfa target two evasion pathways simultaneously, and preclinical work on related agents, including the bispecific antibody YM101 combined with the CCR5 antagonist maraviroc and the immunostimulatory antibody-drug conjugate Y101S, has shown superior tumor control in mouse models. Anti-CD73 antibodies such as oleclumab, CCR4 antagonists such as FLX475, and CTLA-4 blockade round out a therapeutic arsenal whose shared goal is to shift the suppressive balance within the tumor microenvironment decisively back toward the effector cells that can destroy the tumor.
Subject of Research: The role of regulatory T cells in immune suppression and emerging immunotherapies in ovarian cancer
Article Title: Regulatory T cells in ovarian cancer
Article References: Bose, C. K. (2026). Regulatory T cells in ovarian cancer. Discover Immunity, 3(1), Article 18. https://doi.org/10.1007/s44368-026-00034-x
Image Credits: AI Generated
DOI: 10.1007/s44368-026-00034-x
Keywords: regulatory T cells, ovarian cancer, tumor microenvironment, FoxP3, CD8+/Treg ratio, CCL22/CCR4 axis, TGF-beta, immune checkpoint inhibitors, mogamulizumab, immunosuppression, high-grade serous carcinoma, immunotherapy
News Source: Nathaniel Bowman. (October 28, 2026). How Regulatory T Cells Help Ovarian Cancer Hide From the Immune System. Scienmag.
